{"id":1165,"date":"2025-10-29T08:08:15","date_gmt":"2025-10-29T11:08:15","guid":{"rendered":"https:\/\/peledigital.com\/blog\/?p=1165"},"modified":"2025-11-17T10:56:10","modified_gmt":"2025-11-17T13:56:10","slug":"infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025","status":"publish","type":"post","link":"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/","title":{"rendered":"Infec\u00e7\u00f5es por Herpes em Dermatite At\u00f3pica \u2014 Resumo Executivo 2024\/2025"},"content":{"rendered":"\n  <!-- ===== T\u00edtulo ===== -->\n  <header class=\"post-header\">\n    <h1>INFEC\u00c7\u00d5ES POR HERPES EM DERMATITE AT\u00d3PICA<br><small>Resumo Executivo 2024\/2025<\/small><\/h1>\n    <!-- Coloque a imagem de destaque no WordPress e associe ao post -->\n  <\/header>\n\n  <!-- ===== \u00cdndice com \u00c2ncoras ===== -->\n  <nav class=\"post-toc\">\n    <h3>Sum\u00e1rio<\/h3>\n    <ol>\n      <li><a href=\"#epidemiologia\">Epidemiologia e Preval\u00eancia<\/a><\/li>\n      <li><a href=\"#patogenese\">Patog\u00eanese e Suscetibilidade<\/a>\n        <ol>\n          <li><a href=\"#barreira-cutanea\">Disfun\u00e7\u00e3o da Barreira Cut\u00e2nea<\/a><\/li>\n          <li><a href=\"#disfuncao-imune\">Disfun\u00e7\u00e3o Imunol\u00f3gica<\/a><\/li>\n        <\/ol>\n      <\/li>\n      <li><a href=\"#manifestacoes\">Manifesta\u00e7\u00f5es Cl\u00ednicas<\/a><\/li>\n      <li><a href=\"#diagnostico\">Diagn\u00f3stico<\/a><\/li>\n      <li><a href=\"#tratamento\">Tratamento<\/a><\/li>\n      <li><a href=\"#terapias-da\">Impacto dos Tratamentos para DA<\/a><\/li>\n      <li><a href=\"#prevencao\">Preven\u00e7\u00e3o e Manejo de Risco<\/a><\/li>\n      <li><a href=\"#conclusoes\">Conclus\u00f5es e Recomenda\u00e7\u00f5es<\/a><\/li>\n      <li><a href=\"#referencias\">Refer\u00eancias<\/a><\/li>\n    <\/ol>\n  <\/nav>\n\n  <!-- ===== 1. Epidemiologia ===== -->\n  <section id=\"epidemiologia\">\n    <h2>1. Epidemiologia e Preval\u00eancia<\/h2>\n    <ul>\n      <li><strong>22%<\/strong> dos pacientes com DA moderada\u2013grave t\u00eam hist\u00f3ria de <em>eczema herp\u00e9tico<\/em> (EH).<\/li>\n      <li><strong>HSV-1<\/strong> responde por ~<strong>90%<\/strong> dos casos de EH.<\/li>\n      <li>Maior preval\u00eancia em crian\u00e7as\/adolescentes com DA mal controlada; recorr\u00eancia sugere componente gen\u00e9tico.<\/li>\n      <li>Contexto geogr\u00e1fico: Jap\u00e3o com incid\u00eancia elevada de <em>herpes zoster<\/em> em DA (\u2248740,9\/100.000 paciente-ano); na popula\u00e7\u00e3o geral polonesa, herpes labial \u224840,6%.<\/li>\n    <\/ul>\n  <\/section>\n\n  <!-- ===== 2. Patog\u00eanese ===== -->\n  <section id=\"patogenese\">\n    <h2>2. Patog\u00eanese e Mecanismos de Suscetibilidade<\/h2>\n\n    <h3 id=\"barreira-cutanea\">2.1 Disfun\u00e7\u00e3o da Barreira Cut\u00e2nea<\/h3>\n    <ul>\n      <li>Redu\u00e7\u00e3o de lip\u00eddios (\u00e1cidos graxos de cadeia longa) e de <em>ceramidas<\/em> \u00f4mega-esterificadas \u2192 barreira mais perme\u00e1vel.<\/li>\n      <li><strong>COL23A1 rs2973744<\/strong> (col\u00e1geno XXIII) associado a EH: \u2191COL23A1, \u2191sindecan-1\/nectina-1 (entrada do HSV-1), \u2193genes antivirais (IL1R1, IL32, TLR4, IRF1, S100A9, C3, CFH).<\/li>\n    <\/ul>\n\n    <h3 id=\"disfuncao-imune\">2.2 Disfun\u00e7\u00e3o Imunol\u00f3gica<\/h3>\n    <ul>\n      <li><strong>RNase 7<\/strong> limita HSV-1 em queratin\u00f3citos (\u2193replica\u00e7\u00e3o\/plaques). Redu\u00e7\u00e3o na DA lesional \u2192 \u2191suscetibilidade.<\/li>\n      <li><strong>TSLP<\/strong>: forma curta (sfTSLP) tem efeito anti-inflamat\u00f3rio\/antimicrobiano e reduz infectividade; forma longa (lfTSLP) \u00e9 pr\u00f3-tipo 2.<\/li>\n      <li><strong>IL-4<\/strong> prejudica forma\u00e7\u00e3o de c\u00e9lulas T de mem\u00f3ria residentes (\u2193CD103\/CD49a; \u2193resposta ao TGF-\u03b2) \u2192 pior prote\u00e7\u00e3o cut\u00e2nea a HSV.<\/li>\n    <\/ul>\n  <\/section>\n\n  <!-- ===== 3. Manifesta\u00e7\u00f5es ===== -->\n  <section id=\"manifestacoes\">\n    <h2>3. Manifesta\u00e7\u00f5es Cl\u00ednicas<\/h2>\n    <ul>\n      <li>Ves\u00edculas <em>umbilicadas<\/em>, agrupadas, dissemina\u00e7\u00e3o r\u00e1pida; dor e febre frequentes; sobreposi\u00e7\u00e3o em \u00e1reas de DA ativa.<\/li>\n      <li>Diferenciais: varicela, impetigo, <em>eczema vaccinatum<\/em>, dermatite de contato, molusco contagioso.<\/li>\n    <\/ul>\n  <\/section>\n\n  <!-- ===== 4. Diagn\u00f3stico ===== -->\n  <section id=\"diagnostico\">\n    <h2>4. Diagn\u00f3stico<\/h2>\n    <ul>\n      <li><strong>PCR para HSV-1<\/strong> (m\u00e9todo mais sens\u00edvel e espec\u00edfico); cultura viral; sorologia IgM quando necess\u00e1rio; Tzanck (menos espec\u00edfico).<\/li>\n      <li><strong>Diagn\u00f3stico precoce salva tempo e pele:<\/strong> resposta cl\u00ednica t\u00edpica em ~48h com <strong>aciclovir IV<\/strong> quando iniciado cedo.<\/li>\n    <\/ul>\n  <\/section>\n\n  <!-- ===== 5. Tratamento ===== -->\n  <section id=\"tratamento\">\n    <h2>5. Tratamento<\/h2>\n    <h3>5.1 Fase Aguda<\/h3>\n    <ul>\n      <li><strong>Aciclovir IV<\/strong> imediato em casos graves\/suspeita forte; considerar <strong>valaciclovir VO<\/strong> em quadros leves a moderados (7\u201310 dias).<\/li>\n    <\/ul>\n    <h3>5.2 Complica\u00e7\u00f5es<\/h3>\n    <ul>\n      <li>Tratar infec\u00e7\u00e3o bacteriana secund\u00e1ria; considerar <strong>IVIG<\/strong> em casos graves; suporte intensivo conforme necessidade.<\/li>\n    <\/ul>\n  <\/section>\n\n  <!-- ===== 6. Terapias para DA e risco de herpes ===== -->\n  <section id=\"terapias-da\">\n    <h2>6. Impacto dos Tratamentos Sist\u00eamicos para DA<\/h2>\n    <h3>6.1 Dupilumab<\/h3>\n    <ul>\n      <li><strong>Reduz risco<\/strong> de infec\u00e7\u00f5es cut\u00e2neas herp\u00e9ticas e de EH (p.ex., IRR \u2248 0,32 para herpes; \u2248 0,43 para infec\u00e7\u00f5es que exigem tratamento sist\u00eamico).<\/li>\n      <li>Eventos de descontinua\u00e7\u00e3o por AEs s\u00e3o raros; conjuntivite \u00e9 o AE mais frequente.<\/li>\n    <\/ul>\n    <h3>6.2 Inibidores JAK<\/h3>\n    <ul>\n      <li><strong>Aumentam risco<\/strong> de infec\u00e7\u00f5es por herpes, sobretudo <em>herpes zoster<\/em> (maior incid\u00eancia vs. dupilumab\/biol\u00f3gicos).<\/li>\n      <li>Fator de risco independente: <strong>hist\u00f3ria pr\u00e9via de infec\u00e7\u00e3o viral\/f\u00fangica cut\u00e2nea<\/strong>.<\/li>\n      <li><em>Ruxolitinibe t\u00f3pico<\/em> mostra perfil sist\u00eamico mais favor\u00e1vel que JAKi orais.<\/li>\n    <\/ul>\n    <h3>6.3 Tralokinumab<\/h3>\n    <ul>\n      <li>Perfil de seguran\u00e7a consistente; tamb\u00e9m associado a <strong>redu\u00e7\u00e3o<\/strong> de EH (IRR \u2248 0,32) e boa tolerabilidade prolongada.<\/li>\n    <\/ul>\n  <\/section>\n\n  <!-- ===== 7. Preven\u00e7\u00e3o ===== -->\n  <section id=\"prevencao\">\n    <h2>7. Preven\u00e7\u00e3o e Manejo de Risco<\/h2>\n    <h3>7.1 Quem \u00e9 Alto Risco?<\/h3>\n    <ul>\n      <li>Hist\u00f3ria de herpes cut\u00e2neo recorrente; DA grave n\u00e3o controlada; variante <strong>COL23A1 rs2973744<\/strong>; uso de <strong>JAKi<\/strong>; idade \u226565 anos em JAKi.<\/li>\n    <\/ul>\n    <h3>7.2 Estrat\u00e9gias<\/h3>\n    <ul>\n      <li>Avaliar risco antes de JAKi; considerar <strong>profilaxia antiviral<\/strong> em alto risco; monitorar de perto.<\/li>\n      <li><strong>Preferir dupilumab\/tralokinumab<\/strong> em hist\u00f3rico de herpes recorrente.<\/li>\n      <li>Revisar <strong>vacina\u00e7\u00e3o contra zoster<\/strong> antes de iniciar JAKi quando aplic\u00e1vel.<\/li>\n    <\/ul>\n  <\/section>\n\n  <!-- ===== 8. Conclus\u00f5es ===== -->\n  <section id=\"conclusoes\">\n    <h2>8. Conclus\u00f5es e Recomenda\u00e7\u00f5es<\/h2>\n    <ul>\n      <li><strong>EH \u00e9 emerg\u00eancia dermatol\u00f3gica<\/strong> \u2014 suspeitar e tratar imediatamente.<\/li>\n      <li>Suscetibilidade multifatorial: barreira cut\u00e2nea, imunidade inata, gen\u00e9tica (COL23A1, TSLP), \u2193RNase 7.<\/li>\n      <li><strong>Biol\u00f3gicos (dupilumab\/tralokinumab)<\/strong> = menor risco de herpes; <strong>JAKi<\/strong> = maior risco (especialmente zoster).<\/li>\n      <li>Educar paciente para sinais precoces; considerar profilaxia antiviral quando JAKi for indispens\u00e1vel.<\/li>\n    <\/ul>\n  <\/section>\n\n  <!-- ===== Refer\u00eancias ===== -->\n  <section id=\"referencias\">\n    <h2>Refer\u00eancias (sele\u00e7\u00e3o 2024\u20132025)<\/h2>\n    <ul>\n      <li>Coorte\/seguran\u00e7a JAKi e biol\u00f3gicos: \n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40176741\" target=\"_blank\" rel=\"nofollow\">BioDay \u2013 JEADV, 2025<\/a> |\n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39367521\" target=\"_blank\" rel=\"nofollow\">Meta-an\u00e1lise JAKi \u2013 IJD, 2025<\/a>\n      <\/li>\n      <li>EH &#038; patog\u00eanese: \n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39280430\" target=\"_blank\" rel=\"nofollow\">Cureus, 2024<\/a> |\n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39360648\" target=\"_blank\" rel=\"nofollow\">J Med Virol \u2013 RNase 7, 2024<\/a> |\n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39233492\" target=\"_blank\" rel=\"nofollow\">J Med Virol \u2013 sfTSLP, 2024<\/a> |\n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40562081\" target=\"_blank\" rel=\"nofollow\">JACI \u2013 COL23A1, 2025<\/a>\n      <\/li>\n      <li>Biol\u00f3gicos (dupilumab\/tralokinumab): \n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40415482\" target=\"_blank\" rel=\"nofollow\">JEADV \u2013 dupilumab, 2025<\/a> |\n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40879371\" target=\"_blank\" rel=\"nofollow\">BJD \u2013 tralokinumab, 2025<\/a>\n      <\/li>\n      <li>Guias\/vis\u00f5es gerais: \n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39915363\" target=\"_blank\" rel=\"nofollow\">Am J Clin Dermatol, 2025<\/a> |\n        <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40447099\" target=\"_blank\" rel=\"nofollow\">Ann Allergy Asthma Immunol, 2025<\/a>\n      <\/li>\n    <\/ul>\n  <\/section>\n<\/section>\n\n<!-- ===== Estilos r\u00e1pidos opcionais ===== -->\n<style>\n  .post-med {font-family: system-ui, -apple-system, Segoe UI, Roboto, Arial, sans-serif; color:#0a2a33;}\n  .post-header h1 {margin: .5rem 0 1rem; line-height:1.25}\n  .post-resumo {background:#f3fbff; border:1px solid #d8eef7; padding:1rem 1.25rem; border-radius:10px; margin:1rem 0 1.5rem;}\n  .post-toc {background:#f8fafb; border:1px solid #e6edf0; padding:1rem; border-radius:10px; margin:1rem 0 1.5rem;}\n  .post-toc ol {margin:.5rem 0 .25rem 1rem}\n  h2 {margin-top:1.5rem}\n  ul {margin-left:1.1rem}\n  a {color:#0a7cab}\n<\/style>\n\n","protected":false},"excerpt":{"rendered":"<p>Neste artigo, apresentamos uma s\u00edntese pr\u00e1tica e baseada em evid\u00eancias sobre infec\u00e7\u00f5es por herpes em dermatite at\u00f3pica, com foco no eczema herp\u00e9tico (EH) \u2014 complica\u00e7\u00e3o viral potencialmente grave que acomete principalmente pacientes com DA moderada a grave. Revisamos dados recentes de 2024\u20132025 que estimam hist\u00f3ria de EH em cerca de 22% desses pacientes e destacam o predom\u00ednio do HSV-1 (~90%), al\u00e9m de fatores epidemiol\u00f3gicos e cl\u00ednicos relevantes.<\/p>\n<p>Neste artigo, apresentamos os principais mecanismos de suscetibilidade \u2014 barreira cut\u00e2nea comprometida, disfun\u00e7\u00f5es imunes inatas (como redu\u00e7\u00e3o de RNase 7) e variantes gen\u00e9ticas (p.ex., COL23A1 rs2973744 e perfis de TSLP) \u2014 e conectamos esses achados \u00e0 pr\u00e1tica: reconhecimento precoce de les\u00f5es vesiculares umbilicadas de r\u00e1pida dissemina\u00e7\u00e3o, PCR para HSV quando dispon\u00edvel e in\u00edcio imediato de aciclovir nos casos suspeitos. Tamb\u00e9m comparamos a seguran\u00e7a de terapias sist\u00eamicas: dupilumab\/tralokinumab associam-se a menor risco de infec\u00e7\u00f5es herp\u00e9ticas, enquanto JAK inibidores aumentam o risco \u2014 especialmente de herpes zoster.<\/p>\n","protected":false},"author":1,"featured_media":1171,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[111],"tags":[37,174,189,191,186,185,187,190,188],"class_list":["post-1165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermatite-atopica","tag-dermatite-atopica","tag-dupilumab","tag-eczema-herpetico","tag-herpes-zoster","tag-hsv-1","tag-inibidores-jak","tag-profilaxia-antiviral","tag-ruxolitinibe-topico","tag-tralokinumab"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Infec\u00e7\u00f5es por Herpes em Dermatite At\u00f3pica \u2014 Resumo Executivo 2024\/2025 - Pele Digital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Infec\u00e7\u00f5es por Herpes em Dermatite At\u00f3pica \u2014 Resumo Executivo 2024\/2025 - Pele Digital\" \/>\n<meta property=\"og:description\" content=\"Neste artigo, apresentamos uma s\u00edntese pr\u00e1tica e baseada em evid\u00eancias sobre infec\u00e7\u00f5es por herpes em dermatite at\u00f3pica, com foco no eczema herp\u00e9tico (EH) \u2014 complica\u00e7\u00e3o viral potencialmente grave que acomete principalmente pacientes com DA moderada a grave. Revisamos dados recentes de 2024\u20132025 que estimam hist\u00f3ria de EH em cerca de 22% desses pacientes e destacam o predom\u00ednio do HSV-1 (~90%), al\u00e9m de fatores epidemiol\u00f3gicos e cl\u00ednicos relevantes. Neste artigo, apresentamos os principais mecanismos de suscetibilidade \u2014 barreira cut\u00e2nea comprometida, disfun\u00e7\u00f5es imunes inatas (como redu\u00e7\u00e3o de RNase 7) e variantes gen\u00e9ticas (p.ex., COL23A1 rs2973744 e perfis de TSLP) \u2014 e conectamos esses achados \u00e0 pr\u00e1tica: reconhecimento precoce de les\u00f5es vesiculares umbilicadas de r\u00e1pida dissemina\u00e7\u00e3o, PCR para HSV quando dispon\u00edvel e in\u00edcio imediato de aciclovir nos casos suspeitos. Tamb\u00e9m comparamos a seguran\u00e7a de terapias sist\u00eamicas: dupilumab\/tralokinumab associam-se a menor risco de infec\u00e7\u00f5es herp\u00e9ticas, enquanto JAK inibidores aumentam o risco \u2014 especialmente de herpes zoster.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Pele Digital\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T11:08:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-17T13:56:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/peledigital.com\/blog\/wp-content\/uploads\/2025\/10\/ChatGPT-Image-29-de-out.-de-2025-09_12_22-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fabio Francesconi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fabio Francesconi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/\",\"url\":\"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/\",\"name\":\"Infec\u00e7\u00f5es por Herpes em Dermatite At\u00f3pica \u2014 Resumo Executivo 2024\/2025 - Pele Digital\",\"isPartOf\":{\"@id\":\"https:\/\/peledigital.com\/blog\/#website\"},\"datePublished\":\"2025-10-29T11:08:15+00:00\",\"dateModified\":\"2025-11-17T13:56:10+00:00\",\"author\":{\"@id\":\"https:\/\/peledigital.com\/blog\/#\/schema\/person\/e8de861b1668d79f5a37ffe805b71ba5\"},\"breadcrumb\":{\"@id\":\"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/peledigital.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infec\u00e7\u00f5es por Herpes em Dermatite At\u00f3pica \u2014 Resumo Executivo 2024\/2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/peledigital.com\/blog\/#website\",\"url\":\"https:\/\/peledigital.com\/blog\/\",\"name\":\"Pele Digital\",\"description\":\"Vestindo a pele do futuro\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/peledigital.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/peledigital.com\/blog\/#\/schema\/person\/e8de861b1668d79f5a37ffe805b71ba5\",\"name\":\"Fabio Francesconi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/peledigital.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4226959ef05a7ab22bb42e1838c11f56385fd6b30c04a44058dd185b369340ed?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4226959ef05a7ab22bb42e1838c11f56385fd6b30c04a44058dd185b369340ed?s=96&d=mm&r=g\",\"caption\":\"Fabio Francesconi\"},\"sameAs\":[\"https:\/\/blog.peledigital.com\"],\"url\":\"https:\/\/peledigital.com\/blog\/author\/fabio\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Infec\u00e7\u00f5es por Herpes em Dermatite At\u00f3pica \u2014 Resumo Executivo 2024\/2025 - Pele Digital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/","og_locale":"pt_BR","og_type":"article","og_title":"Infec\u00e7\u00f5es por Herpes em Dermatite At\u00f3pica \u2014 Resumo Executivo 2024\/2025 - Pele Digital","og_description":"Neste artigo, apresentamos uma s\u00edntese pr\u00e1tica e baseada em evid\u00eancias sobre infec\u00e7\u00f5es por herpes em dermatite at\u00f3pica, com foco no eczema herp\u00e9tico (EH) \u2014 complica\u00e7\u00e3o viral potencialmente grave que acomete principalmente pacientes com DA moderada a grave. Revisamos dados recentes de 2024\u20132025 que estimam hist\u00f3ria de EH em cerca de 22% desses pacientes e destacam o predom\u00ednio do HSV-1 (~90%), al\u00e9m de fatores epidemiol\u00f3gicos e cl\u00ednicos relevantes. Neste artigo, apresentamos os principais mecanismos de suscetibilidade \u2014 barreira cut\u00e2nea comprometida, disfun\u00e7\u00f5es imunes inatas (como redu\u00e7\u00e3o de RNase 7) e variantes gen\u00e9ticas (p.ex., COL23A1 rs2973744 e perfis de TSLP) \u2014 e conectamos esses achados \u00e0 pr\u00e1tica: reconhecimento precoce de les\u00f5es vesiculares umbilicadas de r\u00e1pida dissemina\u00e7\u00e3o, PCR para HSV quando dispon\u00edvel e in\u00edcio imediato de aciclovir nos casos suspeitos. Tamb\u00e9m comparamos a seguran\u00e7a de terapias sist\u00eamicas: dupilumab\/tralokinumab associam-se a menor risco de infec\u00e7\u00f5es herp\u00e9ticas, enquanto JAK inibidores aumentam o risco \u2014 especialmente de herpes zoster.","og_url":"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/","og_site_name":"Pele Digital","article_published_time":"2025-10-29T11:08:15+00:00","article_modified_time":"2025-11-17T13:56:10+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/peledigital.com\/blog\/wp-content\/uploads\/2025\/10\/ChatGPT-Image-29-de-out.-de-2025-09_12_22-1024x683.png","type":"image\/png"}],"author":"Fabio Francesconi","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Fabio Francesconi","Est. tempo de leitura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/","url":"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/","name":"Infec\u00e7\u00f5es por Herpes em Dermatite At\u00f3pica \u2014 Resumo Executivo 2024\/2025 - Pele Digital","isPartOf":{"@id":"https:\/\/peledigital.com\/blog\/#website"},"datePublished":"2025-10-29T11:08:15+00:00","dateModified":"2025-11-17T13:56:10+00:00","author":{"@id":"https:\/\/peledigital.com\/blog\/#\/schema\/person\/e8de861b1668d79f5a37ffe805b71ba5"},"breadcrumb":{"@id":"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/peledigital.com\/blog\/infeccoes-por-herpes-em-dermatite-atopica-resumo-executivo-2024-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/peledigital.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Infec\u00e7\u00f5es por Herpes em Dermatite At\u00f3pica \u2014 Resumo Executivo 2024\/2025"}]},{"@type":"WebSite","@id":"https:\/\/peledigital.com\/blog\/#website","url":"https:\/\/peledigital.com\/blog\/","name":"Pele Digital","description":"Vestindo a pele do futuro","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/peledigital.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/peledigital.com\/blog\/#\/schema\/person\/e8de861b1668d79f5a37ffe805b71ba5","name":"Fabio Francesconi","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/peledigital.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4226959ef05a7ab22bb42e1838c11f56385fd6b30c04a44058dd185b369340ed?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4226959ef05a7ab22bb42e1838c11f56385fd6b30c04a44058dd185b369340ed?s=96&d=mm&r=g","caption":"Fabio Francesconi"},"sameAs":["https:\/\/blog.peledigital.com"],"url":"https:\/\/peledigital.com\/blog\/author\/fabio\/"}]}},"_links":{"self":[{"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/posts\/1165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/comments?post=1165"}],"version-history":[{"count":6,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/posts\/1165\/revisions"}],"predecessor-version":[{"id":1175,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/posts\/1165\/revisions\/1175"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/media\/1171"}],"wp:attachment":[{"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/media?parent=1165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/categories?post=1165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/tags?post=1165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}